Evana, containing the active substance tranexamic acid, is commonly used across conditions presenting with acute episodes and is relevant for easing symptoms associated with heavy menstrual bleeding (HMB). The medicine is applied across domains where additional symptomatic support is needed. This assistance is commonly applied in scenarios where symptoms intensify, creating noticeable physiological strain, and when supportive management is appropriate. It is commonly used to help with heavy menstrual bleeding, alongside being relevant in situations involving physical discomfort and heightened physiological activity. The medication helps address symptom clusters that may become intense or disruptive during these episodic changes.

“It helps maintain a sense of stability when symptoms are more noticeable.”

Evana may assist with maintaining functional stability and contributes to improved comfort during periods of heightened symptoms. Used in settings where short-term symptomatic assistance is needed, it offers supportive relief that may help patients cope more steadily with symptom fluctuations that interfere with routine activities.

Quick Fact: Supports Symptom Management in Heavy Menstrual Bleeding

Evana (tranexamic acid) is a non-hormonal medication specifically indicated for the treatment of heavy menstrual bleeding (menorrhagia) in adult women with regular periods.

Contraindications and Important Warnings

Evana is not suitable for all patients. It should not be used by individuals with a history of or active thromboembolic disease (e.g., blood clots in the legs or lungs) due to the increased risk of blood clotting. Patients with a known hypersensitivity to tranexamic acid or any component of the tablet should also avoid use. The medication is contraindicated in individuals with severe kidney impairment, certain conditions like disseminated intravascular coagulation (DIC), or a history of convulsions or fits.

Evana is not for use in women under 18 years of age, those who are over 45, or women whose periods have stopped (post-menopausal). It should also be avoided during pregnancy and requires medical consultation if breastfeeding. Individuals taking hormonal contraceptives (like the combined oral pill), other blood clot treatments (e.g., warfarin), or certain other medications must consult a healthcare professional before use. Similarly, patients with irregular periods or blood in the urine between periods should seek medical advice to determine the underlying cause.

Interactions with other medicines and products

This section summarizes the official regulatory information regarding interactions with Evana (Tranexamic Acid), focusing on documented constraints and required avoidance of specific product categories.

---

Interaction Classifications and Restrictions

Classification	Interacting Agents / Classes	Regulatory Constraint Basis
Contraindicated	Hormonal Contraceptives (e.g., Oral Contraceptives)	Increased risk of thromboembolic events.
Contraindicated	Anticoagulants (e.g., Warfarin)	Potential for unacceptable increased thrombotic risk.
Antagonistic Effect	Fibrinolytic Agents (Thrombolytic Therapy)	Reduction or neutralization of the effect of fibrinolytic agents.
Use-with-Caution	Factor IX complex concentrates, Anti-inhibitor Coagulant Complexes	Theoretical increased risk of thrombosis documented in some labels.

---

Official Profile Summary

The official interaction profile for Evana is structured primarily around its pharmacodynamic effects on blood clotting. The most significant constraint involves the avoidance of products that could enhance the risk of thrombosis or counteract the desired effects of other medicines. Regulatory documents formally prohibit co-administration with products like hormonal contraceptives and anticoagulants due to the potential for severe, documented complications. The documented interactions are defined by the need to manage competing effects on the coagulation and fibrinolysis pathways, requiring adherence to explicit do-not-combine rules for the listed agents.

Pharmacodynamic Mechanism of Evana

Evana's mechanism of action is primarily driven by its active diterpenoid components, which act as mild D2 receptor agonists.

This agonistic interaction occurs on the D2 receptors located on the lactotrope cells of the anterior pituitary gland, which is a central component of the neuroendocrine axis. By binding to these receptors, the components initiate an inhibitory signaling cascade, reinforcing the natural tonic control over Prolactin release.

This specific molecular action results in the inhibition of Prolactin synthesis and secretion, leading to a modulation of circulating Prolactin levels. The systemic consequence of reduced Prolactin is the removal of its suppressive effect on the corpus luteum function. This cascade indirectly facilitates increased Progesterone secretion, contributing to the establishment of a Progesterone-dominant physiological environment during the latter phase of the menstrual cycle, which shapes the drug's overall effect profile.

Evana is a pharmaceutical preparation intended exclusively for oral use, administered through various formulations including oral drops, hard capsules, or film-coated tablets. The precise daily dosage regimen for adult women aged 18 and over is strictly dependent on the specific product concentration. This means dosing is highly variable: solid forms may involve taking 4 mg to 20 mg of dry extract once daily, while liquid forms may require 30 to 40 drops of tincture daily. Drops must be diluted in a small amount of liquid before ingestion, whereas tablets and capsules must be swallowed whole and should not be crushed.

The high-level usage protocol requires continuous daily administration. The medicine should be taken consistently for a minimum duration of three months (or three full menstrual cycles) to complete the full treatment course. This structured pattern is key to the administration protocol. Evana is not recommended for use in children or adolescents under 18 years of age due to insufficient data regarding its use in these populations. The medicine is generally administered without strict regard to meals, but adherence to the daily frequency is essential.

Research Evidence: Overview of Studies for Evana (Agnus castus)

---

Clinical Evidence for Premenstrual Syndrome (PMS) Symptom Management

Research exploring the preparation's main substance, Agnus castus, has been primarily conducted through randomized controlled trials (RCTs) and subsequent systematic reviews. These studies compare the preparation against a placebo in adult women with mild to moderate PMS. The research was applied in studies examining patient-reported experiences and outcomes related to physical discomfort, such as mood changes, headache, and cyclical breast pain. Studies were designed to observe and measure how symptom severity changed in the groups receiving the Agnus castus preparation. The findings described in scientific and regulatory summaries reflect a pattern of measurements observed across multiple studies, though the results apply only to the specific populations studied.

---

Clinical Evidence for Menstrual Cycle Irregularities and Hormonal Balance

The research for this indication was evaluated in women experiencing conditions characterized by fluctuating manifestations, such as a temporary physiological imbalance. Studies explored whether the substance was associated with changes in cycle regularity and specific hormone levels. The studies examined outcomes related to systemic or functional imbalance by measuring changes in the length of the menstrual cycle and the duration of the luteal phase. Research focused on observing and measuring hormone levels; findings describe patterns related to prolactin levels in some observed populations. The available evidence includes fewer large-scale RCTs compared to the research base for PMS, and the full extent of long-term effects on the broader endocrine system is not fully established.

---

Research Gaps and What Remains Uncertain

Most published clinical trials focus on research exploring short-term symptom changes over a defined interval. The vast majority of trials had follow-up durations that were limited (typically 3 to 6 cycles), meaning long-term effects are not fully established. There is also limited information for long-term outcomes regarding the sustained use of the preparation beyond six months. The evidence is also limited in certain groups, such as children, older adults, and populations with specific comorbid conditions.

Key Studies & References

1. Vitex agnus-castus Extracts for Female Reproductive Disorders: A Systematic Review of Clinical Trials

Common questions about Evana (FAQ)

Q: What is Evana?

Evana is a prescription medication used to treat Type 2 diabetes mellitus in adults. It helps to control blood sugar levels.

Q: How should I take Evana?

Evana is typically taken once daily, with or without food, as directed by your healthcare provider. It is important to follow the exact dosing instructions provided on your prescription label.

Q: What are common side effects of Evana?

Common side effects may include nausea, diarrhea, and upper respiratory tract infections. These are usually mild and may lessen over time. If you experience persistent or worsening side effects, you should inform your doctor.

Q: What should I do if I miss a dose?

If you miss a dose, take it as soon as you remember, unless it is closer to the time for your next dose. In that case, skip the missed dose and resume your regular schedule. Do not take two doses to make up for a missed one.

Q: Can Evana be taken with other diabetes medications?

Evana may be used alone or in combination with other medications for Type 2 diabetes, such as metformin or insulin. Always discuss all your medications with your healthcare provider to ensure safe and effective use.

Q: How long does it take for Evana to start working?

Evana begins to work soon after you start taking it, but it may take several weeks for the full effect on blood sugar control to be noticeable. Consistent use, alongside diet and exercise, is important for the best results.

Q: Does Evana cause weight changes?

Changes in weight have been observed with Evana. Some patients may experience modest weight loss, while others may not see any significant change. Discuss any concerns about weight with your healthcare provider.

The storage and disposal of Evana (Tranexamic Acid 500 mg tablets) must adhere strictly to official regulatory guidelines.

Official Storage Conditions

Requirement	Constraint
Temperature	Do not store the medicine above 25 C.
Protection	Keep the tablets in the original package and away from the sight and reach of children.
Stability Limit	Do not use the medicine after the expiry date (EXP) printed on the carton.

Official Disposal Instructions

Regulatory instructions prohibit discarding the tablets via wastewater or household waste. All unused or expired medicine must be disposed of according to local pharmaceutical waste programs. You should ask a pharmacist for the correct method to discard the product, as these measures are required to protect the environment and adhere to local disposal requirements.